Following the seminal studies by Bakker et al (2004), we have identified the C‐type lectin domain family 12, member A (CLEC12A) (also named hMICL and CLL‐1) as a stable and reliable leukaemia‐associated marker at diagnosis and as a tool for assessing minimal residual disease in AML (Larsen et al, 2012; Roug et al, 2014). This evidence concerns the gene CLEC12A and leukemia.